A new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature

5Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy that derives from plasmacytoid dendritic cells. The cancer is characterized by aggressive development and dismal prognosis, and due to limited prospective study, there is currently no established standard treatment. In this study, the case of a 77-year old female patient with BPDCN, who presented with a cutaneous lesion on the right of her face, is described. The lesion developed into a serious ulcer due to rapid disease progress, thus, a surgical excision was performed. As the patient refused to receive radiotherapy or haematopoietic stem cell transplantation following surgery, a new palliative combination chemotherapy was administered, comprising gemcitabine, nedaplatin and bleomycin. The therapy gave satisfactory results in terms of short-term treatment response and was well-tolerated. Published literature regarding BPDCN is also reviewed.

Cite

CITATION STYLE

APA

Yang, Y., Xu, Y., Nie, Y., Wang, H., Long, S., & Li, X. (2019). A new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature. Journal of International Medical Research, 47(10), 5281–5288. https://doi.org/10.1177/0300060519871860

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free